Intrexon (NASDAQ:XON) Posts Earnings Results

Intrexon (NASDAQ:XON) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.05, reports. The business had revenue of $35.99 million during the quarter, compared to the consensus estimate of $29.62 million. Intrexon had a negative return on equity of 29.18% and a negative net margin of 368.47%. The business’s quarterly revenue was down 20.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.51) EPS.

Shares of NASDAQ:XON traded down $0.67 during mid-day trading on Friday, reaching $6.95. 2,054,562 shares of the company traded hands, compared to its average volume of 1,095,194. The stock’s 50 day simple moving average is $7.58. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.07 and a beta of 2.22. The company has a current ratio of 3.91, a quick ratio of 3.57 and a debt-to-equity ratio of 0.76. Intrexon has a 52 week low of $3.95 and a 52 week high of $19.94.

In related news, COO Thomas Bostick sold 4,359 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $7.76, for a total transaction of $33,825.84. Following the completion of the transaction, the chief operating officer now directly owns 40,236 shares in the company, valued at approximately $312,231.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Randal J. Kirk acquired 376,932 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of $4.25 per share, with a total value of $1,601,961.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 3,402,182 shares of company stock valued at $15,739,033 and have sold 22,672 shares valued at $173,474. Insiders own 44.00% of the company’s stock.

A number of equities research analysts have issued reports on XON shares. Northland Securities restated a “hold” rating and set a $7.00 price target on shares of Intrexon in a research note on Tuesday, May 14th. Bank of America cut their price target on Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research note on Friday. ValuEngine upgraded Intrexon from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, BidaskClub downgraded Intrexon from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $16.25.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

See Also: Google Finance Portfolio

Earnings History for Intrexon (NASDAQ:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.